Compounds > naltrexone

naltrexone and nystatin a1

naltrexone has been researched along with nystatin a1 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Chang, HK; Han, SM; Jang, MH; Kim, CJ; Kim, KA; Lee, JS; Lim, S; Park, HJ; Shim, I; Shin, MC1
Abe, K; Shirasaki, T; Soeda, F; Takahama, K1

Reviews

1 review(s) available for naltrexone and nystatin a1

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for naltrexone and nystatin a1

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Modulation of Chelidonii herba on glycine-activated and glutamate-activated ion currents in rat periaqueductal gray neurons.
    Clinica chimica acta; international journal of clinical chemistry, 2003, Volume: 337, Issue:1-2

    Topics: Animals; Chelidonium; Dose-Response Relationship, Drug; Ethylmaleimide; Female; Glutamic Acid; Glycine; Ion Channel Gating; Male; Membrane Potentials; Naltrexone; Neurons; Nystatin; Patch-Clamp Techniques; Periaqueductal Gray; Plant Extracts; Rats; Rats, Sprague-Dawley

2003
delta-Opioid receptor antagonists inhibit GIRK channel currents in acutely dissociated brainstem neurons of rat.
    Brain research, 2004, May-01, Volume: 1006, Issue:2

    Topics: Analgesics, Opioid; Animals; Animals, Newborn; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Enkephalin, D-Penicillamine (2,5)-; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Guanosine 5'-O-(3-Thiotriphosphate); Ionophores; Locus Coeruleus; Naltrexone; Narcotic Antagonists; Neurons; Norepinephrine; Nystatin; Patch-Clamp Techniques; Potassium Channels; Potassium Channels, Inwardly Rectifying; Raphe Nuclei; Rats; Serotonin; Thermolysin

2004